Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05087342 · ClinicalTrials.gov registry record · Phase 3
Latino Semaglutide Study
A Phase 3 study, sponsored by Loma Linda University.
- Completed
- Registry status
- Phase 3
- Development phase
- 119
- Enrollment target
NCT05087342 is a Phase 3 study that has completed, run by Loma Linda University. The registered enrollment target is 119 participants.
The verdict
NCT05087342, a Phase 3 study, has completed, sponsored by Loma Linda University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 119 participants
- Enrollment target
Study Summary
The purpose of this study to understand better how this anti-obesity medication works to assist individuals to lose weight and maintain weight loss. This study may lead to the development of other related medications for assisting people with the disease of obesity.
Interventions
- DRUG Placebo
- DRUG Semaglutide 2.4mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2022-12-13 |
| Est. Completion | 2024-05-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05087342
The ClinicalTrials.gov registry entry for NCT05087342 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loma Linda University, which has 237 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05087342 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05087342 about?
NCT05087342 is a clinical study titled "Latino Semaglutide Study". The purpose of this study to understand better how this anti-obesity medication works to assist individuals to lose weight and maintain weight loss. This study may lead to the development of other related medications for assisting people with the disease of obesity.
What is the current status of trial NCT05087342?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 119 participants. The study started on 2022-12-13. Estimated completion is 2024-05-29.
What interventions are being tested in trial NCT05087342?
The interventions under investigation include: Placebo (DRUG), Semaglutide 2.4mg (DRUG).
Who is sponsoring clinical trial NCT05087342?
This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.